Urinary heparanase activity in patients with Type 1 and Type 2 diabetes

Nephrology Dialysis Transplantation

Volumn 27, Issue 7, 2012, Pages 2853-2861

  Rops, Angelique L W M M ^a   Van Den Hoven, Mabel J ^a   Veldman, Bart A ^a   Salemink, Simone ^a   Vervoort, Gerald ^a   Elving, Lammy D ^a   Aten, Jan ^b   Wetzels, Jack F ^a   Van Der Vlag, Johan ^a   Berden, Jo H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

membranous glomerulopathy; Type 1 diabetes; Type 2 diabetes; urinary heparanase activity

Indexed keywords

ALBUMIN; ALDOSTERONE ANTAGONIST; ANGIOTENSIN ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA 2 MICROGLOBULIN; CREATININE; HEPARAN SULFATE; HEPARANASE; MESSENGER RNA; RENIN INHIBITOR;

ADULT; AGE DISTRIBUTION; ALBUMINURIA; ARTICLE; BETA 2 MICROGLOBULIN URINE LEVEL; CONTROLLED STUDY; CREATININE URINE LEVEL; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYMURIA; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TUBULE DAMAGE; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT RESPONSE;

ADULT; AGED; ALBUMINURIA; BLOTTING, WESTERN; CASE-CONTROL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR BASEMENT MEMBRANE; GLUCURONIDASE; HEPARITIN SULFATE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RENIN-ANGIOTENSIN SYSTEM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84864418353     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr732     Document Type: Article

References (42)

1. Brenner BM, Baylis C, Deen WM. Transport of molecules across renal glomerular capillaries. Physiol Rev 1976; 56: 502-534.
2. Raats CJ, Bakker MA, Hoch W et al. Differential expression of agrin in renal basement membranes as revealed by domain-specific antibodies. J Biol Chem 1998; 273: 17832-17838.
3. Tamsma JT, van den Born J, Bruijn JA et al. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia 1994; 37: 313-320.
4. van den Born J, van den Heuvel LP, Bakker MA et al. Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases. Kidney Int 1993; 43: 454-463.
5. Wapstra FH, Navis GJ, van Goor H et al. ACE inhibition preserves heparan sulfate proteoglycans in the glomerular basement membrane of rats with established adriamycin nephropathy. Exp Nephrol 2001; 9: 21-27.
6. Raats CJ, Van Den Born J, Berden JH. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int 2000; 57: 385-400.
7. van den Hoven MJ, Rops AL, Bakker MA et al. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 2006; 70: 2100-2108.
8. Kramer A, van den Hoven M, Rops A et al. Induction of glomerular heparanase expression in rats with adriamycin nephropathy is regulated by reactive oxygen species and the renin-angiotensin system. J Am Soc Nephrol 2006; 17: 2513-2520.
9. Levidiotis V, Kanellis J, Ierino FL et al. Increased expression of heparanase in puromycin aminonucleoside nephrosis. Kidney Int 2001; 60: 1287-1296.
10. Levidiotis V, Freeman C, Tikellis C et al. Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. J Am Soc Nephrol 2004; 15: 68-78.
11. Levidiotis V, Freeman C, Punler M et al. A synthetic heparanase inhibitor reduces proteinuria in passive Heymann nephritis. J Am Soc Nephrol 2004; 15: 2882-2892.
12. Levidiotis V, Freeman C, Tikellis C et al. Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease. Nephrology (Carlton) 2005; 10: 167-173.
13. Maxhimer JB, Somenek M, Rao G et al. Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes 2005; 54: 2172-2178.
14. Wijnhoven TJ, van den Hoven MJ, Ding H et al. Heparanase induces a differential loss of heparan sulphate domains in overt diabetic nephropathy. Diabetologia 2008; 51: 372-382.
15. Vlodavsky I, Friedmann Y, Elkin M et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999; 5: 793-802.
16. Hulett MD, Freeman C, Hamdorf BJ et al. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 1999; 5: 803-809.
17. Abboud-Jarrous G, Rangini-Guetta Z, Aingorn H et al. Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase. J Biol Chem 2005; 280: 13568-13575.
18. Shafat I, Pode D, Peretz T et al. Clinical significance of urine heparanase in bladder cancer progression. Neoplasia 2008; 10: 125-130.
19. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006; 38: 2018-2039.
20. Shafat I, Zcharia E, Nisman B et al. An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun 2006; 341: 958-963.
21. Holt RC, Webb NJ, Ralph S et al. Heparanase activity is dysregulated in children with steroid-sensitive nephrotic syndrome. Kidney Int 2005; 67: 122-129.
22. Katz A, Van-Dijk DJ, Aingorn H et al. Involvement of human heparanase in the pathogenesis of diabetic nephropathy. Isr Med Assoc J 2002; 4: 996-1002.
23. Lewis EJ, Xu X. Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of lowmolecular weight heparin. Diabetes Care 2008; 31Suppl 2S202-S207.
24. Han J, Woytowich AE, Mandal AK et al. Heparanase upregulation in high glucose-treated endothelial cells is prevented by insulin and heparin. Exp Biol Med (Maywood) 2007; 232: 927-934.
25. Petermann AT, Pippin J, Krofft R et al. Viable podocytes detach in experimental diabetic nephropathy: potential mechanism underlying glomerulosclerosis. Nephron Exp Nephrol 2004; 98: e114-e123.
26. van den Hoven MJ, Rops AL, Vlodavsky I et al. Heparanase in glomerular diseases. Kidney Int 2007; 72: 543-548.
27. Jacobs EM, Vervoort G, Branten AJ et al. Atrial natriuretic peptide increases albuminuria in type I diabetic patients: evidence for blockade of tubular protein reabsorption. Eur J Clin Invest 1999; 29: 109-115.
28. van den Born J, van den Heuvel LP, Bakker MA et al. Monoclonal antibodies against the protein core and glycosaminoglycan side chain of glomerular basement membrane heparan sulfate proteoglycan: characterization and immunohistological application in human tissues. J Histochem Cytochem 1994; 42: 89-102.
29. van de Lest CH, Versteeg EM, Veerkamp JH et al. Altered composition of urinary heparan sulfate in patients with COPD. Am J Respir Crit Care Med 1996; 1544 Pt 1952-958.
30. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
31. van den Hoven MJ, Waanders F, Rops AL et al. Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species. Nephrol Dial Transplant 2009; 24: 2637-2645.
32. Rutjes N, Claessen N, Deegens J et al. The role of heparanase in the pathophysiology of idiopathic nephrotic syndrome Abstract. Nephrology 2005; 10SupplA117-A232.
33. Vlodavsky I, Goldshmidt O, Zcharia E et al. Molecular properties and involvement of heparanase in cancer progression and normal development. Biochimie 2001; 83: 831-839.
34. Rops AL, van der Vlag J, Jacobs CW et al. Isolation and characterization of conditionally immortalized mouse glomerular endothelial cell lines. Kidney Int 2004; 66: 2193-2201.
35. Rops AL, van den Hoven MJ, Baselmans MM et al. Heparan sulfate domains on cultured activated glomerular endothelial cells mediate leukocyte trafficking. Kidney Int 2008; 73: 52-62.
36. van Bruggen MC, Kramers K, Hylkema MN et al. Decrease of heparan sulfate staining in the glomerular basement membrane in murine lupus nephritis. Am J Pathol 1995; 146: 753-763.
37. Raats CJ, Bakker MA, van den Born J et al. Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic syndrome. J Biol Chem 1997; 272: 26734-26741.
38. Chen S, Wassenhove-McCarthy DJ, Yamaguchi Y et al. Loss of heparan sulfate glycosaminoglycan assembly in podocytes does not lead to proteinuria. Kidney Int 2008; 74: 289-299.
39. Harvey SJ, Jarad G, Cunningham J et al. Disruption of glomerular basement membrane charge through podocyte-specific mutation of agrin does not alter glomerular permselectivity. Am J Pathol 2007; 171: 139-152.
40. Rossi M, Morita H, Sormunen R et al. Heparan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney. Embo J 2003; 22: 236-245.
41. van den Hoven MJ, Wijnhoven TJ, Li JP et al. Reduction of anionic sites in the glomerular basement membrane by heparanase does not lead to proteinuria. Kidney Int 2008; 73: 278-287.
42. Gambaro G, van der Woude FJ. Glycosaminoglycans: use in treatment of diabetic nephropathy. J Am Soc Nephrol 2000; 11: 359-368.